16 Results for "

MCAO model

" in MedChemExpress (MCE) Product Catalog:
Products (16)

16 Results for "MCAO model" in MCE Product Catalog:

Cat. No.: HY-N3847
CAS No.: 38965-51-4
Synonyms: Eriodictyol 7-O-β-D-glucoside
Eriodictyol-7-O-glucoside (Eriodictyol 7-O-β-D-glucoside), a flavonoid, is an Nrf2 activator. Eriodictyol-7-O-glucoside exhibits significant scavenging effects on both hydroxyl radicals and superoxide anions, with IC50 values of 0.28 mM and 0.30 mM, respectively. Eriodictyol-7-O-glucoside increases the nuclear localization of Nrf2 and induces the expression of the Nrf2/ARE-dependent genes. Eriodictyol-7-O-glucoside provides protection against oxygen and glucose deprivation (OGD)-induced oxidative insult. Eriodictyol-7-O-glucoside demonstrates neuroprotective efficacy in a rat model of focal cerebral ischemia (MCAO). Eriodictyol-7-O-glucoside can be used for the study of stroke .
loading...
    loading...
Cat. No.: HY-N7905
CAS No.: 520-14-9
Myricetin 3'-glucoside is an orally active glycosylated flavonoid. Myricetin 3'-glucoside inhibits the cerebral ischemia-induced elevation of inflammatory cytokine levels, including TNF-α, IL-6 and IL-1β. Myricetin 3'-glucoside reverses the cerebral ischemia-mediated downregulation of Bcl-2 protein levels and reduces the cerebral ischemia-induced upregulation of Bax protein levels. Myricetin 3'-glucoside reduces cerebral infarct volume, increases the number of Nissl bodies, and improves neurological function scores in a rat model of middle cerebral artery occlusion (MCAO). Myricetin 3'-glucoside can be used in cerebral ischemia-related research .

loading...
    loading...
Cat. No.: HY-162359
CAS No.: 2573211-25-1
Target:  

IRAK

BIO-7488 is an orally active, selective and blood-brain barrier permeable IRAK4 inhibitor, with an IC50 value of 0.5 nM. BIO-7488 inhibits the production of pro-inflammatory cytokines (IL-1β, TNFα, IL-6) and demonstrates anti-inflammatory effects in both LPS (HY-D1056) and distal hypoxic-middle cerebral artery occlusion (DH-MCAO) ischemic stroke model. BIO-7488 can be used for the study of neuroinflammatory-related diseases, particularly ischemic stroke .
loading...
    loading...
Cat. No.: HY-126049
CAS No.: 88929-35-5
Purity:  98.78%
Synonyms: (S)-(-)-Oxiracetam; (S)-ISF2522
Target:  

Apoptosis

Research Areas:  

Neurological Disease

(S)-oxiracetam (S-ORC) is an inhibitor targeting apoptosis. S-ORC reduces brain infarct size and lessens neurological dysfunction in middle cerebral artery occlusion/reperfusion (MCAO/R) models. S-ORC prevents neuronal apoptosis via activating PI3K/Akt/GSK3β signaling pathway via α7 nAChR after ischemic stroke. S-ORC can prevent neuronal death after ischemic stroke .
loading...
    loading...
Cat. No.: HY-169914
CAS No.: 130152-35-1
Synonyms: JO 1784 hydrochloride
Target:  

Sigma Receptor

Igmesine hydrochloride (JO 1784 hydrochloride) is a selective σ-1 receptor agonist (IC50 = 39 nM) with oral activity and blood-brain barrier penetration. Igmesine hydrochloride stimulates duodenal bicarbonate secretion in rats via a σ1/vagal/CCK-A-dependent pathway, without antisecretory activity. Igmesine hydrochloride centrally blocks CRF-mediated gastrin-inhibitory effects, and in TMT toxicity and MCAO focal ischemia models, it downregulates PTBBS, reduces NOS, and modulates M1/M2 density. Igmesine hydrochloride is used in research on duodenal ulcers, Alzheimer's disease, and related diseases .
loading...
    loading...
Cat. No.: HY-178464
CAS No.: 3065634-19-4
RIPK1-IN-34 is a selective, brain-penetrant RIPK1 inhibitor (IC50 = 126.70 nM) with almost no inhibitory effect on RIPK3 (IC50 > 10, 000 nM). RIPK1-IN-34 offers substantial neuroprotection by inhibiting the phosphorylation of RIPK1, RIPK3, and mixed lineage kinase domain-like pseudokinase (MLKL) within the necroptosis pathway. RIPK1-IN-34 shows the neuroprotective effect in a rat middle cerebral artery occlusion (MCAO) model. RIPK1-IN-34 can be used for the study of anti-acute ischemic stroke (AIS) .
loading...
    loading...
Cat. No.: HY-159928
Neuroprotective agent 8 (compound AA-9) is an oral active neuroprotective agent by anti-oxidative stress and anti-inflammation. Neuroprotective agent 8 activates PGC-1α and inhibits NLRP3 in the rat MCAO ischemic stroke model .
loading...
    loading...
Cat. No.: HY-174127
Target:  

P2Y Receptor

Research Areas:  

Neurological Disease

P2Y1 antagonist 3 (compound 36b) is a blood-brain barrier (BBB)-penetrant P2Y1 antagonist with an IC50 of 0.50 μM. P2Y1 antagonist 3 exhibits protective effects in a rat middle cerebral artery occlusion (MCAO) model and demonstrates neuroprotective activity against oxidative stress by upregulating nuclear Nrf2 protein levels .
loading...
    loading...
Cat. No.: HY-100458
CAS No.: 2185855-51-8
Target:  

NO Synthase

Research Areas:  

Neurological Disease

SCR-4026 is a neuroprotective agent with blood-brain barrier penetration ability. SCR-4026 exerts neuroprotective effects by disrupting the interaction between neuronal nNOS and PSD9, with an IC50 of 6.3 μM. SCR-4026 alleviates N-methyl-D-aspartate (NMDA)-induced excitotoxic damage in primary cortical neurons, and also protects neurons in the oxygen-glucose deprivation (OGD) model. SCR-4026 can reduce the cerebral infarct volume in the rat middle cerebral artery occlusion (MCAO) reperfusion model. SCR-4026 can be used for the study of stroke .
loading...
    loading...
Cat. No.: HY-172455
CAS No.: 3023854-95-4
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

TREK inhibitor-3 (Cpd8l) is a selective and BBB-permeable TREK-1 inhibitor with an IC50 of 0.81 μM. TREK inhibitor-3 has neuroprotective effects, which can significantly reduce the death of cortical neurons induced by oxygen-glucose deprivation/reoxygenation (OGD/R) and improve brain injury in mice models of middle cerebral artery occlusion/reperfusion (MCAO/R). TREK inhibitor-3 can be used in the research of ischemic stroke .
loading...
    loading...
Cat. No.: HY-168770
CAS No.: 862377-51-3
Research Areas:  

Cardiovascular Disease

Cl-Necrostatin-1 is a RIPK1 inhibitor. Cl-Necrostatin-1 can also inhibit TNF-α-induced necroptosis in Jurkat cells deficient in Fas-associated death domain protein (FADD; EC50 = 180 nM), a modification that prevents caspase activation in response to death-domain receptor signaling. Cl-Necrostatin-1 can also reduce infarct size in a mouse model of middle cerebral artery occlusion (MCAO). Cl-Necrostatin-1 is used for research in cardiovascular and cerebrovascular diseases .
loading...
    loading...
Cat. No.: HY-173142
Target:  

Drug Derivative

Research Areas:  

Neurological Disease

Neuroprotective agent 7 (Compound 13) is a BBB-penetrable neuroprotective agent. Neuroprotective agent 7 has a powerful neuroprotective effect and can reduce the cerebral infarct area in the MCAO rat model. Neuroprotective agent 7 can be used in the research of diseases such as cerebral ischemia .
loading...
    loading...
Cat. No.: HY-181549
CAS No.: 3080627-61-5
PDE4-IN-32 (Compound B05) is a selective, blood-brain barrier permeable PDE4B and PDE4D inhibitor with IC50 values of 13.7 nM and 23.8 nM, respectively. PDE4-IN-32 promotes the recovery of motor and cognitive function in MCAO/R mouse models. PDE4-IN-32 reduces cerebral edema. PDE4-IN-32 can be used for the research of ischemic stroke .
loading...
    loading...
Cat. No.: HY-182068
Target:  

iGluR

NFI23 is a blood-brain barrier-penetrant GluN2B-NMDAR inhibitor, with an IC50 of 1.31 μM and a Ki of 5.98 nM against GluN2B-NMDAR. NFI23 reduces NMDA-induced Ca 2+ influx and ROS production, maintains mitochondrial membrane potential, inhibits neuronal apoptosis, and restores the expression of p-ERK1/2. NFI23 exerts neuroprotective effects against NMDA-induced cytotoxicity and in the rat middle cerebral artery occlusion (MCAO) model. NFI23 can be used for the research of ischemic stroke .
loading...
    loading...
Cat. No.: HY-169914A
CAS No.: 140850-73-3
Synonyms: JO 1784
Igmesine (JO 1784) is a selective σ-1 receptor agonist (IC50 = 39 nM) with oral activity and blood-brain barrier penetration. Igmesine stimulates duodenal bicarbonate secretion in rats via a σ1/vagal/CCK-A-dependent pathway, without antisecretory activity. Igmesine centrally blocks CRF-mediated gastrin-inhibitory effects, and in TMT toxicity and MCAO focal ischemia models, it downregulates PTBBS, reduces NOS, and modulates M1/M2 density. Igmesine is used in research on duodenal ulcers, Alzheimer's disease, and related diseases .
loading...
    loading...
Cat. No.: HY-180806
CAS No.: 3065634-42-3
RIPK1-IN-39 (compound 2) is a potent and selective RIPK1 inhibitor (IC50 = 69.40 nM) exhibiting >100-fold selectivity over RIPK3 (IC50 = 6946 nM). RIPK1-IN-39 protects HT-22 and HT-29 cells from necroptosis by inhibiting the phosphorylation and activation of the RIPK1-RIPK3-MLKL pathway. RIPK1-IN-39 demonstrates neuroprotective effects in a rat model of middle cerebral artery occlusion (MCAO). RIPK1-IN-39 can be used for acute ischemic stroke (AIS) research .
loading...
    loading...
  • 1